Form 4: Kiniksa Director Exercises Vested Options and Sells Shares for Over $30 Each

Barry D. Quart, a Director at Kiniksa Pharmaceuticals International, plc, executed a series of stock option exercises and subsequent sales of Class A Ordinary Shares over three days in June 2025.

Summary

• On June 9, 2025, Barry D. Quart exercised options to acquire 6,900 Class A Ordinary Shares at an exercise price of $3.8 per share and simultaneously sold these 6,900 shares at a weighted average price of $30.26 per share.
• On June 10, 2025, Mr. Quart exercised options for an additional 8,212 Class A Ordinary Shares at $3.8 per share and sold these 8,212 shares at a weighted average price of $30.36 per share.
• On June 11, 2025, Mr. Quart exercised options for 12,336 Class A Ordinary Shares at $3.8 per share and sold these 12,336 shares at a weighted average price of $30.39 per share.
• All options exercised were fully vested and exercisable.
• Following these transactions, Mr. Quart's direct beneficial ownership of Class A Ordinary Shares remained at 12,546 shares, as the acquired shares from option exercises were immediately sold.
• The total number of derivative securities (share options) beneficially owned by Mr. Quart decreased from 20,548 to 0 over the three-day period as all options were exercised.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, these transactions appear to be routine exercises of vested options for liquidity, rather than a signal of negative company performance. The significant spread between exercise and sale price is positive for the insider.

Positives

• The director's ability to exercise options at a low price ($3.8) and sell shares at a significantly higher market price (over $30) indicates a substantial gain on the exercised options.
• The options were fully vested and exercisable, indicating maturity of the equity compensation plan.

Negatives

• The transactions represent insider selling, which, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• "This transaction was executed in multiple trades through a broker-dealer at prices ranging between $30.00 and $30.52. The price reported in this column reflects a weighted average sales price." (Regarding 06/09/2025 sale)
• "This transaction was executed in multiple trades through a broker-dealer at prices ranging between $30.28 and $30.5801. The price reported in this column reflects a weighted average sales price." (Regarding 06/11/2025 sale)
• "The option is fully vested and exercisable."

Industry Context

Insider transactions, such as option exercises and subsequent share sales, are common occurrences across all industries, including the pharmaceutical sector. These transactions often relate to executive compensation and liquidity events for individuals.

Stakeholder Impact

• Shareholders: May observe the director's sale of shares, which could be interpreted in various ways depending on market sentiment and the context of the transactions (e.g., pre-planned 10b5-1 sales vs. discretionary sales).

Key Dates

Keywords

Kiniksa Pharmaceuticals, KNSA, Form 4, Insider Trading, Stock Options, Share Sale, Director, Beneficial Ownership, Equity Compensation